CG Oncology Undervalued Going Into A Busy 2026

Core Insights - Biotech stocks are primarily driven by data, but share prices do not always reflect the underlying value indicated by that data [1] Company Analysis - CG Oncology, Inc. (CGON) has experienced data releases that suggest a discrepancy between its stock price and the value implied by its data [1]